文献速递主动脉疾病

多机构成本分析显示当前 Medicare 对复杂血管腔内主动脉修复的报销不足

Current Medicare reimbursement for complex endovascular aortic repair is inadequate based on results from a multi-institutional cost analysis.
PubMed 文献 · J Vasc Surg · 2023-09-20

该多机构成本分析纳入5家高容量复杂主动脉中心共125例复杂血管腔内主动脉修复(comEVAR),比较植入器械成本与Medicare加权报销。结果显示所有病例平均器械成本为每例28470美元,占中位报销35755美元的80%;FEVAR平均器械成本26499美元显著低于chEVAR的32122美元(P < .002)。作者认为现行报销使高容量复杂主动脉中心处于财务劣势,建议重新考虑过时的DRG编码与报销。

要点

  • 所有分析病例平均植入器械成本为每例28470美元,占中位Medicare报销35755美元的80%。
  • FEVAR平均器械成本每例26499美元显著低于chEVAR每例32122美元(P < .002)。
  • 器械成本分别占报销的74%(FEVAR)和90%(chEVAR),作者建议重新考虑现行DRG编码与报销。

核心结论

  • 植入器械成本单独即占comEVAR每例加权Medicare总报销的绝大部分,且chEVAR显著比FEVAR昂贵。
  • 作者认为对这些病例报销不足使高容量、高复杂度主动脉中心处于明显财务劣势。
  • 作者建议为优化患者照护,重新考虑先前建立的、过时的comEVAR的DRG编码与Medicare报销。

研究设计与样本

  • 多机构成本分析,纳入5家地理分布不同、高容量复杂主动脉中心。
  • 分析各中心连续25例近期因近肾、肾旁及肾上腹主动脉瘤行comEVAR的植入式主髂动脉及分支支架器械成本数据。
  • 排除破裂、胸主动脉瘤、再干预及医师改良EVAR病例,也排除非植入设备的辅助成本。
  • 数据合并后分为总体成本组及FEVAR或chEVAR两个单独成本组,并与DRG编码268/269的加权Medicare报销比较。
  • 中位器械成本来自覆盖超过3000家医疗中心的独立采购联盟,为真实机构成本数据。

主要发现

  • 共分析125例:70例FEVAR和53例chEVAR;2例联合FEVAR/chEVAR纳入总成本分析但排除于直接比较。
  • 中位Medicare报销计算为每例35755美元。
  • 所有分析病例合并平均植入器械成本为每例28470美元,占中位报销的80%(28470/35755)。
  • FEVAR平均器械成本每例26499美元显著低于chEVAR每例32122美元(P < .002)。
  • 器械成本占报销比例:FEVAR为74%(26499/35755),chEVAR为90%(32122/35755)。

临床怎么用

  • 作者建议重新考虑先前建立的、过时的comEVAR的DRG编码与Medicare报销,以优化患者照护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Complex endovascular juxta-, para- and suprarenal abdominal aortic aneurysm repair (comEVAR) is frequently accomplished with commercially available fenestrated (FEVAR) devices or off-label use of aortoiliac devices with parallel branch stents (chEVAR). We sought to evaluate the implantable vascular device costs incurred with these procedures as compared with standard Medicare reimbursement to determine the financial viability of comEVAR in the modern era. METHODS: Five geographically distinct institutions with high-volume, complex aortic centers were included. Implantable aortoiliac and branch stent device cost data from 25 consecutive, recent, comEVAR in the treatment of juxta-, para-, and suprarenal aortic aneurysms at each center were analyzed. Cases of rupture, thoracic aneurysms, reinterventions, and physician-modified EVAR were excluded, as were ancillary costs from nonimplantable equipment. Data from all institutions were combined and stratified into an overall cost group and two, individual cost groups: FEVAR or chEVAR. These groups were compared, and each respective group was then compared with weighted Medicare reimbursement for Diagnosis-Related Group codes 268/269. Median device costs were obtained from an independent purchasing consortium of >3000 medical centers, yielding true median cost-to-institution data rather than speculative, administrative projections or estimates. RESULTS: A total of 125 cases were analyzed: 70 FEVAR and 53 chEVAR. Two cases of combined FEVAR/chEVAR were included in total cost analysis, but excluded from direct FEVAR vs chEVAR comparison. Median Medicare reimbursement was calculated as $35,755 per case. Combined average implantable device cost for all analyzed cases was $28,470 per case, or 80% of the median reimbursement ($28,470/$35,755). Average FEVAR device cost per case ($26,499) was significantly lower than average chEVAR cost per case ($32,122; P < .002). Device cost was 74% ($26,499/$35,755) of total reimbursement for FEVAR and 90% ($32,122/$35,755) for chEVAR. CONCLUSIONS: Results from this multi-institutional analysis show that implantable device cost alone represents the vast majority of weighted total Medicare reimbursement per case with comEVAR, and that chEVAR is significantly more costly than FEVAR. Inadequate Medicare reimbursement for these cases puts high-volume, high-complexity aortic centers at a distinct financial disadvantage. In the interest of optimizing patient care, these data suggest a reconsideration of previously established, outdated, Diagnosis-Related Group coding and Medicare reimbursement for comEVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Brinster CJ, Money SR, Hayson A, et al. Current Medicare reimbursement for complex endovascular aortic repair is inadequate based on results from a multi-institutional cost analysis. J Vasc Surg. 2023. PMID: 37734569. doi:10.1016/j.jvs.2023.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。